A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Inclusion Criteria:

- Be 18 years old at the time the informed consent form is signed

- Have a histologically or cytologically confirmed adenocarcinoma or poorly
differentiated carcinoma of the prostate

- Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL
(1.73 nM)

- Experienced disease progression after having received at least 1 but no more than 2
prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based
chemotherapy, for castration-resistant disease

- Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other
homologous recombination deficiency

Exclusion Criteria:

- Active second malignancy, with the exception of curatively treated non-melanoma skin
cancer, carcinoma in situ, or superficial bladder cancer

- Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any
platinum-based chemotherapy

- Symptomatic and/or untreated central nervous system metastases

- Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would,
in the opinion of the investigator, interfere with absorption of rucaparib